All In Biotech

Drug Trial Radar · NCT01839175

Concomitant Administration of a New Hexavalent Vaccine With a Meningococcal Serogroup C Conjugate Vaccine in Healthy Infants During Primary Series Immunisation Followed by Booster Vaccination

A Phase III Open-label Randomised Study to Evaluate the Immunogenicity and Safety of the Concomitant Administration of a New Hexavalent DTaP-IPV-HepB-PRP-T Combined Vaccine (Hexavalent Vaccine) Given at 2, 3, and 4 Months of Age With a Meningococcal Serogroup C Conjugate (MenC) Vaccine Given at 2 and 4 Months of Age

Last checked: Nov 20, 2026Latest source record: Sep 11, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 350 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

350

Actual

Start

Apr 2013

Primary completion

Jul 2014

Study completion Feb 2015

Sponsor

Lead sponsor
Sanofi Pasteur, a Sanofi CompanySanofi (SNY)
Sponsor type
Industry
First posted
Apr 24, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Prevention
Who can join
All sexes, from 46 days, up to 76 days
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Primary Series Primary objectives * To demonstrate that the concomitant administration of the hexavalent vaccine with a meningococcal serogroup C conjugate vaccine is non inferior to the administration of the hexavalent vaccine without a MenC vaccine concomitantly in term of seroprotection rate for hepatitis B one month after the third dose of the hexavalent vaccine * To demonstrate that the concomitant administration of a MenC vaccine with the hexavalent vaccine induces an acceptable response for MenC in term of seroprotection rate (SPR) one month after the second dose of MenC Booster Primary objectives \- To describe the immunogenicity of a booster dose of the hexavalent vaccine and of a meningococcal group ACWY conjugate (MenACWY) vaccine either co-administered at 12 months of age or given separately.

Conditions

  • Neisseria Meningitidis
  • Bacterial Infections
  • Virus Diseases

Interventions

  • Hexavalent vaccineBiological

    0.5 mL intramuscular injection at 2, 3 and 4 months of age (primary series) 0.5 mL intramuscular injection at 12 or 13 months of age (booster)

  • NeisVac-CBiological

    0.5 mL intramuscular injection at 2 and 4 months of age

  • Prevenar 13Biological

    0.5 mL intramuscular injection at 2 and 4 months of age (primary series) 0.5 mL intramuscular injection at 13 months of age (booster)

  • RotaTeqBiological

    2 mL oral administration at 2, 3 and 4 months

  • NimenrixBiological

    0.5 mL intramuscular injection at 12 months

  • M-M-RVAXPROBiological

    0.5 mL intramuscular or subcutaneous injection at 13 months of age

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of subjects with an anti-hepatitis B concentration ≥10 IU/mLTime frame: Month 5 (One month after dose 3 of the hexavalent vaccine and dose 2 of MenC vaccine)
  2. Proportion of subjects with an anti-MenC titre ≥1:8 dilTime frame: Month 5 (One month after dose 3 of the hexavalent vaccine and dose 2 of MenC vaccine)

Locations

11 sites in 1 country. Site status is shown where the registry gives one.

  • Sanofi Pasteur MSD Investigational Site 003

    Espoo, Finland

  • Sanofi Pasteur MSD Investigational Site 001

    Helsinki, Finland

  • Sanofi Pasteur MSD Investigational Site 002

    Helsinki, Finland

  • Sanofi Pasteur MSD Investigational Site 011

    Jarvenpaa, Finland

  • Sanofi Pasteur MSD Investigational Site 010

    Kokkola, Finland

  • Sanofi Pasteur MSD Investigational Site 004

    Oulu, Finland

  • Sanofi Pasteur MSD Investigational Site 005

    Pori, Finland

  • Sanofi Pasteur MSD Investigational Site 009

    Seinäjoki, Finland

  • Sanofi Pasteur MSD Investigational Site 006

    Tampere, Finland

  • Sanofi Pasteur MSD Investigational Site 007

    Turku, Finland

  • Sanofi Pasteur MSD Investigational Site 008

    Vantaa, Finland

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.